<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111992</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2106</org_study_id>
    <nct_id>NCT03111992</nct_id>
  </id_info>
  <brief_title>Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma</brief_title>
  <official_title>Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and identify the recommended&#xD;
      doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients&#xD;
      with relapsed and/or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Actual">March 2, 2020</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is comprised of 3 treatment arms:&#xD;
Single agent CJM112 (Arm A)&#xD;
A fixed dose of PDR001 in combination with CJM112 (Arm B)&#xD;
A fixed dose of PDR001 in combination with LCL161 (Arm C)&#xD;
Patients may switch from treatment on Arm A to the corresponding CJM112 dose level on Arm B at the time of disease progression if that dose level has been declared safe, and if patients do not have any DLTs on single agent CJM112. Otherwise, patients will switch to a lower dose level that has been declared safe. No other cross-over between treatment arms is allowed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients reporting dose limiting toxicities</measure>
    <time_frame>2 months</time_frame>
    <description>number of patients reporting dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients who experience a treatment-related adverse event after being treated with a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients requiring interruptions after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of patients requiring a dose interruption</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients treated with single agent CJM112, or PDR001 in combination with either CJM112 or LCL161, who discontinued treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of patients discontinuing treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients requiring a dose reduction after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of patients requiring a dose reduction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of PDR001 and CJM112</measure>
    <time_frame>First 6 months of study treatment</time_frame>
    <description>Presence and/or concentration of anti-PDR001, and anti-CJM112 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Determine ORR in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Determine BOR in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Determine PFS in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Determine DCR in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of PDR001, CJM112 and LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PDR001, CJM112 and LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of PDR001, CJM112 and LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of PDR001, CJM112 and LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration vs time profile of PDR001, CJM112 and LCL161</measure>
    <time_frame>24 months</time_frame>
    <description>Concentration vs time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of single agent CJM112</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of CJM112 in combination with a fixed dose of PDR001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of LCL161 in combination with a fixed dose of PDR001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>Anti-PD1 antibody</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJM112</intervention_name>
    <description>Anti-IL-17A antibody</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCL161</intervention_name>
    <description>Oral small molecule SMAC-mimetic</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to provide written informed consent before any screening procedures.&#xD;
&#xD;
          -  Male or female patients ≥18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of multiple myeloma who have received two or more&#xD;
             lines of therapy including an IMiD and PI, and are relapsed and/or refractory to their&#xD;
             most recent line of therapy. Patients who have received a prior autologous bone marrow&#xD;
             transplant and otherwise meet the inclusion criteria are eligible for this study.&#xD;
&#xD;
          -  Must have measurable disease defined by at least 1 of the following 3 measurements:&#xD;
&#xD;
          -  Serum M-protein ≥ 0.5 g/dL OR&#xD;
&#xD;
          -  Urine M-protein ≥ 200 mg/24 hours OR&#xD;
&#xD;
          -  Serum free light chain (FLC) &gt; 100 mg/L of involved FLC&#xD;
&#xD;
          -  All patients must be willing to undergo a mandatory serial bone marrow aspirate and/or&#xD;
             biopsy at screening and subsequently following treatment for the assessment of&#xD;
             biomarker/pharmacodynamics and disease status. Exceptions may be considered after&#xD;
             documented discussion with Novartis.&#xD;
&#xD;
        Other inclusion criteria included in the protocol might apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic chronic steroid therapy (≥10mg /day of prednisone or equivalent), or&#xD;
             any immunosuppressive therapy within 7 days of first dose of study treatment. Topical,&#xD;
             inhaled, nasal, or ophthalmic steroids are allowed.&#xD;
&#xD;
          -  Malignant disease, other than that being treated in this study. Exceptions to this&#xD;
             exclusion include the following: malignancies that were treated curatively and have&#xD;
             not recurred within 2 years prior to study treatment; completely resected basal cell&#xD;
             and squamous cell skin cancers, and completely resected carcinoma in situ of any type.&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease other than patients with vitiligo,&#xD;
             residual hypothyroidism only requiring hormone replacement, psoriasis not requiring&#xD;
             systemic treatment or conditions not expected to recur.&#xD;
&#xD;
          -  Patients with prior known toxicity attributed to PD-1 or PDL-1 directed therapy, which&#xD;
             led to discontinuation of these agents, will be excluded from the PDR001 containing&#xD;
             arms of the study.&#xD;
&#xD;
          -  Patients with prior known toxicity from IL-17A directed therapy, which led to&#xD;
             discontinuation of the study treatment, will be excluded from CJM112 containing arms&#xD;
             of the study.&#xD;
&#xD;
          -  Any of the following clinical laboratory results during screening (i.e., within 28&#xD;
             days before the first dose of study treatment):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1,000/mm3 without growth factor support within&#xD;
                  7 days prior to testing&#xD;
&#xD;
               -  Platelet count &lt; 75,000 mm3 without transfusion support within 7 days prior to&#xD;
                  testing&#xD;
&#xD;
               -  Bilirubin &gt; 1.5 times the upper limit of the normal range (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 times the&#xD;
                  ULN&#xD;
&#xD;
               -  Calculated creatinine clearance &lt; 30 ml/min according to Cockcroft-Gault equation&#xD;
                  Other exclusion criteria included in the protocol might apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=717</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma,</keyword>
  <keyword>Multiple Myeloma,</keyword>
  <keyword>Hematologic Diseases,</keyword>
  <keyword>Myeloma, Multiple,</keyword>
  <keyword>Myeloma-Multiple,</keyword>
  <keyword>Programmed Cell Death 1 Receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

